Members of the Bacteroides fragilis group of organisms are the most frequently recovered anaerobic bacterial pathogens of humans. They are usually cultured from infections involving inoculation of a sterile site by colonic flora as a result of contamination after abdominal surgery, ruptured appendicitis, bowel ischemia, infected decubitus ulcers, colonic cancer, endometritis, pelvic inflammatory disease, and abdominal trauma (4, 8). Less frequently, infections such as primary bacteremia, amnionitis, endocarditis, biliary tract sepsis, meningitis, and osteomyelitis may also occur (4). This report marks the fifth year of an ongoing survey of B. fragilis group susceptibilities in the United States (1, 10, 11). In previous analyses, we described instances of drug resistance at various clinical centers (1). We also documented a difference in resistance rates by species (1).
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In this report, the in vitro activities of several new
1-lactam drugs were tested. Species isolation rates were tabulated by body site, and resistance patterns of organisms isolated from particular sites are detailed. Analyses of rates of drug resistance and cross resistance were performed. Isolates. Nonduplicated clinical isolates of the B. fragilis group were collected by the eight centers making up the study group (1) and were sent to the Tufts anaerobe laboratory from January 1984 through December 1985. Species identification was performed by established methodology (5) . The clinical site of isolation was recorded.
MATERIALS AND METHODS
Susceptibility testing. Susceptibility testing was done by an agar dilution technique with the Steers replicator. The medium used was brain heart infusion broth and agar supplemented with vitamin K1 and 5% laked sheep erythrocytes. Anaerobic chamber techniques were used as previously described (13) . For ticarcillin-clavulanic acid testing, the clavulanic acid concentration was kept constant at 2 ,ugIml, while the ticarcillin component was varied.
Data analysis. Data were stored, retrieved, and analyzed by Dbase II (Ashton-Tate, Culver City, Calif.), Lotus 1-2-3 (Lotus Development Corp., Cambridge, Mass.), and statistical programs written in BASIC developed for the IBM-PC computer (International Business Machines, Inc., Boca Raton, Fla.) or in a Multiplan spreadsheet (Micropro, San Rafael, Calif.) for the model 200 Tandy computer (Fort Worth, Tex.) by George Cuchural. is now 10%. The cefoxitin resistance rate decreased in six of the seven other hospitals in 1985, which accounted for the overall nationwide decrease. In 1985, cefoxitin showed relatively uniform activity at the various centers. The lowest cefoxitin resistance rate was 2% at Loyola University, while the highest was 10% at Tufts University. The lowest piperacillin resistance rate was 8% at Tufts University, while the highest was 20% at the University of Michigan. Also, in 1985, cefotetan displayed a higher rate of variability among centers, with a low rate of 15% at the University of Miami/ Jackson Memorial Medical Center and a high rate of 36% at the University of Michigan. Because of the very low rates of resistance to imipenem and ticarcillin-clavulanic acid, no clustering of resistance could be detected.
The susceptibility of the various species within the B. fragilis group revealed no changes from the pattern reported in 1981 through 1983 ( 1981  755  8  12  22  54  57  6  63  1982  531  10  7  12  48  54  3  59  1983  555  16  8  12  42  54  7  67  1984  551  12  12  15  39  54  9  63  1985  669  5  11  15  41  54  5 species in the group, B. fragilis continued to be the most the sample size was too small to draw conclusions. The susceptible to the ,-lactam drugs. B. distasonis, B. vulgatus, tendency toward higher rates of P-lactam drug resistance in and B. thetaiotaomicron were more resistant, particularly to perinatal sites is probably accounted for by the high percentthe cephamycins: cefoxitin, moxalactam, and cefotetan.
age of recovery of the more ,-lactam-resistant B. distasonis Cefotetan showed the highest variation in activity among the and B. vulgatus species. The increased resistance of the species. The lowest cefotetan resistance rate was found with blood isolates, however, cannot be explained in a similar B. fragilis (8%), and the highest rate was found with B.
fashion. Fecal isolates were generally more susceptible. ovatus (83%). Piperacillin and clindamycin showed less Analysis of drug cross resistance is seen in Table 7 . species variation in activity. Imipenem and ticarcillin-clavuCefoxitin-, piperacillin-, moxalactam-, and cefotetan-resislanic acid showed essentially no variation. tant isolates were highly resistant to the other P-lactams and The distribution of B. fragilis species by clinical site is modestly more resistant to clindamycin. Isolates resistant to seen in Table 5 . B. fragilis, the species isolated most ceftizoxime, cefotaxime, cefoperazone, and ceftazidime frequently, was found in 63% of cultures. Conversely, nonwere not as highly cross resistant. Clindamycin-resistant B. fragilis isolates accounted for 37% of all clinical isolates.
isolates had statistically significant higher resistance rates to B. distasonis and B. vulgatus species were found at statistipiperacillin, moxalactam, cefotaxime, and cefotetan. The B. cally significantly higher rates in perinatal isolates, while B. distasonis isolate, which was resistant to imipenem and fragilis species were found at lower rates. B. fragilis species ticarcillin-clavulanic acid, was resistant to all other Pwere isolated from blood, skin and soft tissue, and drainage lactams and clindamycin. It was susceptible to chloramphensites more frequently than chance would allow. B. ovatus icol and metronidazole.
was isolated less frequently from the bloodstream than expected. The resistance rates by site of isolation are seen in DISCUSSION Table 6 . Blood isolates tended to be more resistant to most antibiotics except imipenem, ticarcillin-clavulanic acid,
The results of our study indicate that several of the chloramphenicol, and metronidazole, for which very low or currently available ,B-lactam antimicrobial agents are active no resistance was found. Perinatal isolates were generally against the B. fragilis group of organisms. Imipenem and more resistant to ,B-lactam antibiotics and less resistant to ticarcillin-clavulanic acid were the most active ,B-lactam clindamycin. Bone isolates tended to be more resistant, but drugs, while cefoxitin, piperacillin, and moxalactam also fragilis group infections who failed therapy owing to a possible drug resistance to cefoxitin, piperacillin, moxalactam, or cefotetan should be switched to imipenem, ticarcillin-clavulanic acid, metronidazole, or chloramphenicol pending susceptibility testing. Patients with isolates resistant to ceftizoxime, cefotaxime, cefoperazone, or ceftazidime are probably common, and most of these isolates will be susceptible to imipenem, ticarcillin-clavulanic acid, cefoxitin, clindamycin, chloramphenicol, or metronidazole.
Local susceptibility patterns are of great importance for guiding empiric therapy of infections caused by this group of organisms, since these infections are frequently serious and life threatening.
